About this Journal Submit a Manuscript Table of Contents
Sarcoma
Volume 2013 (2013), Article ID 450478, 12 pages
http://dx.doi.org/10.1155/2013/450478
Research Article

Insulin-Like Growth Factor 1 Receptor as a Therapeutic Target in Ewing Sarcoma: Lack of Consistent Upregulation or Recurrent Mutation and a Review of the Clinical Trial Literature

1Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
2Department of Gastroenterology and Nutrition, Boston Children's Hospital, 300 Longwood Avenue Boston, MA 02115, USA
3Department of Pathology and Human Oncology & Pathogenesis Program, Room S-801, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue New York, NY 10065, USA
4Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
5Division of Pediatric Oncology, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA

Received 27 July 2012; Revised 5 December 2012; Accepted 9 December 2012

Academic Editor: Maria Tsokos

Copyright © 2013 Alison O'Neill et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Alison O'Neill, Nilay Shah, Naamah Zitomersky, et al., “Insulin-Like Growth Factor 1 Receptor as a Therapeutic Target in Ewing Sarcoma: Lack of Consistent Upregulation or Recurrent Mutation and a Review of the Clinical Trial Literature,” Sarcoma, vol. 2013, Article ID 450478, 12 pages, 2013. doi:10.1155/2013/450478